Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Double-blinded, Placebo Controlled Study of Xilonix for Improving Survival in Metastatic Colorectal Cancer

Next Previous
X
Search
Trial Profile

Phase III Double-blinded, Placebo Controlled Study of Xilonix for Improving Survival in Metastatic Colorectal Cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bermekimab (Primary) ; Megestrol
  • Indications Carcinoma; Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms XCITE
  • Sponsors XBiotech

    • Most Recent Events

    • 06 Nov 2017 This trial has been completed in Czech Republic (End date:2017-07-07).
    • 12 Jul 2017 This trial has been completed in Belgium (End date:2017-06-29).
    • 09 Jun 2017 According to an XBiotech media release, the IDMC had no safety concerns from the unblinded analysis. However, the committee recommended the early termination of the study since the findings were not sufficient to meet efficacy or the threshold for continuation, which involved a prospectively defined acceptance boundary for the interim analysis of less than or equal to p = 0.08.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top